MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Optimi Health Corp (CSE:OPTI)

5.800 -0.040 (-0.68%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,201
Open 5.810
Bid (Size) 5.800 (100)
Ask (Size) 5.850 (100)
Prev. Close 5.840
Today's Range 5.790 - 6.050
52wk Range 0.1050 - 10.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial
Via Investor Brand Network
Topics Supply Chain
News headline image
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from... 
From OPTIMI HEALTH CORP.
Via GlobeNewswire

Performance

YTD
+1741.3%
+1741.3%
1 Month
-27.0%
-27.0%
3 Month
+1935.1%
+1935.1%
6 Month
+1631.3%
+1631.3%
1 Year
+3525.0%
+3525.0%

More News

Read More
BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program
Via Investor Brand Network
News headline image
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
From OPTIMI HEALTH CORP.
Via GlobeNewswire
BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product
Via Investor Brand Network
News headline image
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
From OPTIMI HEALTH CORP.
Via GlobeNewswire
NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
Via Investor Brand Network
News headline image
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
From OPTIMI HEALTH CORP.
Via GlobeNewswire
PsychedelicNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
Via Investor Brand Network
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
Via Investor Brand Network
News headline image
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Via PressReach
Topics Regulatory Compliance
PsychedelicNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift
Via Investor Brand Network
News headline image
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Via PressReach
News headline image
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Via PressReach
Topics Regulatory Compliance
News headline image
Optimi Health Completes MD-MA Export for PTSD Treatment Under Australia’s Authorised Prescriber Scheme
Via PressReach
News headline image
Optimi Health Completes First 2026 Production of MD-MA and Psilo Capsules
Via PressReach
News headline image
Early Warning Press Release in Accordance with National Instrument 62-103
Via Newsfile
Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson
Via PressReach
News headline image
Psychedelic Drugs Prove Their Worth In Clinical Trials
Via PressReach
News headline image
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
Via PressReach
Topics Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
Via FinancialNewsMedia
Topics Cannabis
Optimi Health and ATMA Journey Centers to Send a Clinical Trial Application to Health Canada for Phase I Natural Psilocybin and MDMA
Via PressReach
Topics Supply Chain
Psychedelics May Make People Less Afraid of Death
Via FinancialNewsMedia
Topics Supply Chain
Psychedelics Use Among Young Adults Reaches All-Time High
Via FinancialNewsMedia
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
Via FinancialNewsMedia
Topics Supply Chain

Frequently Asked Questions

Is Optimi Health Corp publicly traded?
Yes, Optimi Health Corp is publicly traded.
What exchange does Optimi Health Corp trade on?
Optimi Health Corp trades on the Canadian Securities Exchange
What is the ticker symbol for Optimi Health Corp?
The ticker symbol for Optimi Health Corp is OPTI on the Canadian Securities Exchange
What is the current price of Optimi Health Corp?
The current price of Optimi Health Corp is 5.800
When was Optimi Health Corp last traded?
The last trade of Optimi Health Corp was at 06/25/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story